Skip to content
drillr.ai

TEVA

Teva Pharmaceutical Industries Limited

NYSE · ILHealthcareDrug Manufacturers - Specialty & Generic
$31.00-3.22%

Price as of Jul 20, 2026

TEVA news

Teva Pharmaceutical Industries Limited news

A server-rendered, paginated timeline of the latest available company news.

  1. Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

    Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus(®) (ocrelizumab) for Multiple Sclerosis * Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus(®) (ocrelizumab), including both intravenous and subcutaneous formulations. * Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations. * Agreement reflects both companies’ com

    Business Wire ·

  2. Teva Releases Q2 2026 Aide Memoire

    TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the “Investors” page on its website. Q2 2026 Aide Memoire (https://www.globenewswire.com/Tracker?data=WLSDJcDqH-WWBGBmaL8oZukjx9poWROlMMsVGwI43n8yl7pz7cianrGss0_h-AbzW6lZLJA0nuDPzA1tRggiyO33IBJuJQy5snUQW_jcPc0G6SlXsK2-ok_JpwVurLPbE_mRZ9LUA7ClYJsL7_DDGvZ5fRJaNt-w5fU-qXNe6LM=) Teva has compiled this document with public inform

    Globe Newswire ·

  3. Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

    * NDA submission supported by positive Phase 3 data recently published in JAMA Neurology. * Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations * Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved. TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today

    Globe Newswire ·

  4. Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

    TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here (https://www.globenewswire.com/Tracker?data=0bwgkHruOB56bwQ

    Globe Newswire ·

  5. Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

    * Ecopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations.  * The acquisition expands Teva’s innovative pipeline in a specialized area of neuroscience with significant unmet need and is expected to support near- and long-term growth.  * At closing, Teva paid $700 million consideration with the potential for up to an additiona

    Globe Newswire ·

  6. Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

    REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio(®) (vedolizumab) lyophilized vial for intravenous administration. Under a partnership with Teva

    Globe Newswire ·

  7. Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

    REYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the resubmission to the U.S. Food and Drug Administration (FDA) of Biologics License Applications (BLAs) for AVT05, a proposed biosimilar to Simponi(®) and Simponi Aria(®) (golimumab), and AVT06, a proposed biosimilar to Eylea(®) (aflibercept) 2 mg. Under a partnersh

    Globe Newswire ·

  8. Teva to Present at the Goldman Sachs Global Healthcare Conference

    PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. The fireside chat will begin at 8:00 A.M. Eastern Time. To access live webcasts of the presentations, please visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Pres

    Globe Newswire ·

  9. The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

    * The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation(1) administered every four weeks. * If approved, TEV-‘749 could help fill a significant unmet need in available schizophrenia treatment options by addressing the lack of a viable long-acting olanzapine formulation. * Teva is committed to advancing this innovative treatment option, strengthening its scientific leadership in complex neurological conditions as part of i

    Globe Newswire ·

  10. Teva to Present at the BofA Securities Health Care Conference

    PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 12, 2026. The presentation will begin at 9:20 A.M. Pacific Time (12:20 P.M. Eastern Time). To access live webcasts of the presentations, please visit Teva’s Investor Relations website at https://ir.tevapharm.c

    Globe Newswire ·

  11. Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

    * Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced environmental impact. * Through its global access to medicines programs, Teva reached nearly 8 million people through product donations around the world. * 39% reduction in Teva’s Scope 1 and 2 GHG emissions since 2019 and 32% reduction in Scope 3 GHG emissions since 2020—exceeding 25% reduction targets. * More than 99% of active employees completed compliance

    Globe Newswire ·

  12. Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

    TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here (https://www.globenewswire.com/Tracker?data=MVEaZRob6J9FGT1

    Globe Newswire ·

  13. Teva Releases Q1 2026 Aide Memoire

    TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website. Q (https://www.globenewswire.com/Tracker?data=iTnzQ63thJPFj5xWmrk7lTY0PlqXEncbqVvM-QZurtVUvfRwoNQcvpY-h3LR_5v4A8KjU9gjwbKWhpYQ-VcxWxLJFoHsrO267k56iptS1D9MNXPoHSeEE7IQDenpMW8T)1 (https://www.globenewswire.com/Tracker?data=HsayudYh-v1uqXQDTgjDcM3pndq_GopzEX1-KylywJJuDAX-v_Eah5Ae5Aqu-hpQ2Sver

    Globe Newswire ·

  14. Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

    * Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1A * Duvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn’s disease (CD) * Agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and drive long-term growth PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industr

    Globe Newswire ·